There are currently 1995 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
NCT05696717
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
Recruiting
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by kill... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
NCT06663072
Recruiting
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Metastatic Pancreatic Neuroendocrine Tumor
Register for Updates
Islet Transplantation in Patients With "Brittle" Type I Diabetes
NCT01630850
Recruiting
The purpose of this study is to learn about the safety of islet transplantation for Type 1 diabetes mellitus, which may provide more normal control of blood sugar without the need for insulin shots. Islets are special clusters of cells within the pancreas that produce insulin. These cells will be obtained from cadaver (non-living) donors and given to subjects by vein.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/19/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1
Register for Updates
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456
Recruiting
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Advanced Solid Tumor
Register for Updates
Genomic Predictors of Recurrent Pregnancy Loss
NCT05444283
Recruiting
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/19/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Recurrent Pregnancy Loss
Register for Updates
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
NCT06742957
Recruiting
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Site 12108, Chicago, Illinois
Conditions: Plaque Type Psorisis
Register for Updates
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
NCT03587272
Recruiting
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
12/19/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Sickle Cell Disease
Register for Updates
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT03493425
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Register for Updates
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
NCT05832307
Recruiting
This study plans to learn more about whether a stakeholder-informed, standardized inpatient vaccination program will increase influenza vaccination rates of hospitalized children across US pediatric health systems. The first part of the study is to form a multidisciplinary team of stakeholders, including parents, providers, nurses, pharmacists, informaticists, data analysts and communication experts across three sites in synthesizing a best practice implementation guide for an inpatient influenz... Read More
Gender:
ALL
Ages:
Between 6 months and 99 years
Trial Updated:
12/18/2024
Locations: Ann and Robert Lurie's Children Hospital of Chicago, Chicago, Illinois
Conditions: Influenza
Register for Updates
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
Recruiting
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.
Gender:
ALL
Ages:
Between 6 years and 8 years
Trial Updated:
12/18/2024
Locations: Ilinois College of Optometry, Chicago, Illinois
Conditions: Myopia, Juvenile Myopia, Myopia Progression
Register for Updates